Effects of Bergamot and Hawthorn on LDL and HDL Particle Size
Bergamot supplementation appears to favorably shift LDL particles toward larger, less atherogenic sizes while reducing small dense LDL, though evidence for hawthorn's effects on particle size remains insufficient for clinical recommendations.
Bergamot Extract Effects
LDL Particle Size Changes
The most compelling evidence comes from a 6-month prospective study demonstrating that bergamot extract (150 mg flavonoids daily) significantly altered LDL particle distribution 1:
- Large LDL particles (LDL-1) increased from 41.2% to 49.6% (p < 0.0001)
- Small dense LDL particles decreased significantly:
- LDL-3: reduced from 14.5% to 9.0% (p < 0.0001)
- LDL-4: reduced from 3.2% to 1.5% (p = 0.0053)
- LDL-5: reduced from 0.3% to 0.1% (p = 0.0133)
This shift is clinically meaningful because small, dense LDL particles are more atherogenic—they're more susceptible to oxidation and more easily penetrate arterial walls 2. The atherogenic phenotype (phenotype B) characterized by small dense LDL is associated with hypertriglyceridemia, low HDL-C, abdominal obesity, and insulin resistance 2.
HDL Particle Size
While bergamot increased HDL-cholesterol levels (from 1.3 to 1.4 mmol/L, p < 0.0007) 1, specific data on HDL particle size changes are not reported in available studies. The guidelines note that larger HDL particle size is consistently associated with decreased CAD risk 2, but bergamot's direct effects on HDL particle size remain uncharacterized.
Additional Lipid Effects
Bergamot also produced:
- Total cholesterol reduction: 6.6 to 5.8 mmol/L (p < 0.0001)
- LDL-cholesterol reduction: 4.6 to 3.7 mmol/L (p < 0.0001)
- Triglyceride reduction: 1.8 to 1.5 mmol/L (p = 0.0020)
- Carotid intima-media thickness reduction: 1.2 to 0.9 mm (p < 0.0001) 1
Hawthorn Effects
Evidence for hawthorn's effects on LDL and HDL particle size is extremely limited. A 2026 review indicates hawthorn may regulate lipid metabolism through multiple mechanisms including suppression of hepatic lipogenesis, enhancement of fatty acid β-oxidation, and modulation of cholesterol metabolism 3. However, no specific data on particle size distribution are available in the provided evidence.
Clinical Context and Caveats
Important Limitations
Combination products may not work: A 2025 RCT found that combining bergamot with plant sterols, artichoke extract, and hydroxytyrosol showed no significant LDL-cholesterol lowering compared to placebo 4. This suggests potential ingredient interactions that may interfere with bergamot's mechanisms.
Population variability: Genetic factors, dietary habits, and ethnicity may influence responses. A 2026 Asian population study showed more modest effects (7.0% LDL-C reduction) 5 compared to the original Caucasian study.
Particle size vs. particle number: Guidelines emphasize that larger HDL particle size is protective 2, while small dense LDL is more atherogenic 2. However, current guidelines prioritize LDL-C, non-HDL-C, or ApoB as treatment targets rather than particle size measurements 6, 7.
Clinical Recommendation Framework
For patients with moderate hypercholesterolemia seeking nutraceutical approaches:
- Bergamot monotherapy (150 mg flavonoids daily) may be considered based on demonstrated particle size benefits 1
- Avoid complex combination products until better evidence emerges 4
- Monitor lipid panels at 2-3 months to assess individual response
- Particle size testing is not routinely recommended for clinical decision-making 6—focus on standard lipid parameters (LDL-C, non-HDL-C, or ApoB)
Hawthorn cannot be recommended for particle size modification due to insufficient evidence, though it may have broader metabolic effects requiring further investigation 3.